Operator Ian Cooney We encourage you to review the section entitled Forward-Looking Statements in our press release, which applies to this call. Also, please refer to our SEC filings, which can be found on our website and the SEC's website for a discussion of numerous factors that may impact our future performance. We also discuss certain non-GAAP measures. Important information on our use of these measures and reconciliation to U.S. GAAP may be found in our earnings release. Joe Selsavage Ms. Wojcicki also ...

EXHIBIT 99.1 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results SOUTH SAN FRANCISCO, Calif., May 23, 2024 -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024 (FY24), which ended March 31, 2024. Key Results and Recent Developments "The Company had a productive fourth quarter and solid end to the year, continuing to add value for members of 23andMe+ and advan ...

SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024 (FY24), which ended March 31, 2024. Key Results and Recent Developments "The Company had a productive fourth quarter and solid end to the year, continuing to add value for members of 23andMe+ and advancing our clinical stage assets," said Anne Wojcicki, Co-Founder & CEO o ...

SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (NASDAQ:ME), and a leading telemedicine provider, is now offering Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI), prescription erectile dysfunction (ED) medication STENDRAⓇ (avanafil) through its telehealth platform. Working directly with STENDRAⓇ manufacturer Petros Pharmaceuticals, Lemonaid Health is able to offer the fast-acting ED medication at improved pricing. With one in 10 men estimated to h ...

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fourth quarter and full fiscal year 2024 (FY2024) after the market closes on Thursday, May 23, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter ...

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fourth quarter and full fiscal year 2024 (FY2024) after the market closes on Thursday, May 23, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarte ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

KEY TAKEAWAYS23andMe's CEO, Anne Wojcicki, is seeking to take the DNA-testing company private less than three years after it went public in a SPAC deal.Wojcicki holds voting power of 49.99% in the company, so a third-party acquisition is nearly impossible.The company was hit by a large data hack late last year. 23andMe (ME) chief executive Anne Wojcicki is seeking to take the DNA-testing company private less than three years after it went public, the firm said in a Securities and Exchange Commission (SEC) f ...

23andMe CEO Anne Wojcicki is considering a proposal to take the genetic testing company private after its stock price has tumbled more than 95% from its 2021 highs.Wojcicki is working with advisors and plans to begin speaking to possible financing sources and partners, according to a filing with the U.S. Securities and Exchange Commission late Wednesday. She "wishes to maintain control" of the company and will "not be willing to support any alternative transaction," the filing said.The former billionaire co ...

23andMe May Disappear as Public Stock Altayb / Getty Images Battered 23andMe Holding Co. (NASDAQ: ME), its shares driven down to penny stock levels, may disappear from the public markets completely. That is if its CEO can take the company private. If not, 23andMe may run out of money.CEO Anne Wojcicki has told a special committee of the 23andMe board that she will begin to look for funding to buy out public investors. According to an SEC filing, “Ms. Wojcicki also indicated that she wishes to maintain con ...